BioMarin Pharmaceutical (BMRN) closed the last trading session at $70.49, gaining 10.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) is anticipated to release its earnings data before the market opens on Thursday, February 27th. Analysts expect BioMarin Pharmaceutical to post ...

While the job market is tough for life sciences professionals right now, it won’t always be. Employers must continue striving ...

Smartleaf Asset Management LLC grew its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 111.2% in the 4th quarter, according to the company in its most recent 13F ...

Alexander Hardy; President, Chief Executive Officer, Director; Biomarin Pharmaceutical Inc Brian Mueller; Chief Financial Officer, Executive Vice President; Biomarin Pharmaceutical Inc Cristin ...

Net income was up a robust 525% year over year, rising to $125 million. BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results. BioMarin Pharmaceutical ...

BioMarin is amassing a portfolio of genetic-disease therapeutics, making historical comparisons with Genzyme (acquired by Sanofi) difficult to avoid. Commercialization and research and development ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Detailed price information for Biomarin Pharmaceuticals (BMRN-Q) from The Globe and Mail including charting and trades.

Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target BioMarin reported strong Q4 results and Oppenheimer ...